Peptide Testing Labs: How to Test Your Peptides for Purity

What Do Peptide Testing Labs Actually Do?

Peptide testing labs measure what is in a vial. A lab report is not an FDA approval, and it does not make a product legal. Three separate systems decide those questions. One is lab accreditation to ISO/IEC 17025. One is the FDA's 503A bulks list. The third is the banned list of WADA, the World Anti-Doping Agency.

This content is for educational purposes only and is not medical advice. Nothing here is a guide to research use or to treatment. A qualified clinician can advise on any health decision.

What Does Peptide Purity Testing Actually Involve?

Peptide purity testing usually means a few tests. Each one answers a different question.

HPLC, or high performance liquid chromatography, separates a sample into its parts. A 2025 review looked at drug rules from the FDA and its European peers (Elsayed 2025). It says one type of HPLC is commonly used to split the peptide from impurities and measure it. The same review lists LC-MS as the test that gives molecular weight. LC-MS pairs HPLC with mass spectrometry, which weighs molecules. The weight helps show the powder is the molecule on the label. An endotoxin test looks for endotoxin, a toxin that comes from bacteria.

The gap between a label and a lab result can be large. Researchers in Hungary bought semaglutide from illegal online pharmacies with no prescription (Ashraf 2024). Semaglutide is the drug in Ozempic. Three vials arrived. Their purity tested at 7.7% to 14.37%. The labels claimed 99%. Endotoxin was found in all of the samples.

NMR, or nuclear magnetic resonance, is another way to check a peptide. It reads the structure of a molecule. A 2019 study set out an NMR method that checks identity and purity at once (Choules 2019). The team tried it on peptides such as oxytocin.

What Should a Peptide COA Testing Report Show?

A peptide COA testing report, or certificate of analysis, is the document a lab issues with its results. A certificate of analysis is only as good as what it discloses. Our sources criteria list seven checks. Three of them are about what the lab report itself must show. One is HPLC purity with the chromatogram shown. One is a mass spectrometry identity check. The last is a certificate from a named third-party lab. A chromatogram is the actual trace the machine drew, not a summary number.

A single number with no method behind it cannot be checked. Our guide on reading a peptide certificate of analysis shows where each element should appear on the document.

What Is Third-Party Peptide Testing, and Why Does Independence Matter?

Third-party peptide testing means a lab with no business tie to the seller tests the product. A supplier's own certificate covers whatever the seller chooses to disclose. It is a claim, not proof. That is the difference between a test a vendor commissioned about itself and a test somebody else ran.

Which Peptide Testing Companies Do People Ask About?

Names people search for with peptide testing include Finnrick, Janoshik, Chromate, BT Labs, Vanguard and ACS Labs. That list comes from US search data we pulled from Ahrefs on 7 August 2026. Naming them is not a recommendation. We have not audited any testing lab, and we do not intend to. The same checks apply to every name on the list.

The first is a current ISO/IEC 17025 certificate number that matches the public registry. The second is raw chromatogram data on the report. If a report names a lab other than the brand on top, these checks apply to that lab. Being searched for does not show whether a lab is accredited today.

How Do You Check a Peptide Testing Lab's Accreditation?

A peptide testing lab's accreditation can be checked against a public registry. ISO/IEC 17025 is the world standard for how well test labs work. In the US, the federal standards agency NIST runs a lab program called NVLAP. The V stands for voluntary. Its rules include ISO/IEC 17025 (NIST).

NVLAP gives each lab a certificate and a scope. The scope lists the tests the lab is accredited for. NVLAP also keeps a public directory of accredited labs. If a lab gives no certificate number, or points only to its own sales page, its accreditation cannot be checked against the registry.

Does Peptide Testing Decide Legal Status?

Peptide testing does not decide legal status. Section 503A is the part of US drug law for compounding pharmacies. These pharmacies mix drugs for one patient's prescription. Under 503A, a raw drug must meet an official drug standard or be part of an approved drug (FDA). Otherwise it must be on FDA's 503A bulks list.

FDA's compounding safety page was updated in April 2026. It lists BPC-157, TB-500 and KPV among substances previously in Category 2. That is FDA's list of raw drugs with serious safety risks. Their nominations were withdrawn by the people who put them forward. Removal from Category 2 did not add any of them to the 503A bulks list. FDA still lists their safety risks on its compounding safety page.

The PCAC is an outside panel that gives FDA advice on compounding. It met on 23 and 24 July 2026 to look at seven peptides (FDA). BPC-157, KPV and TB-500 were among them. FDA's own papers for that meeting leaned against adding BPC-157 or TB-500 to the list. For BPC-157, FDA said there was not enough safety data from people (FDA). For TB-500, FDA found no human data by any route (FDA).

NCPA, a pharmacists' trade group, reported the vote (NCPA). It said the panel backed six of the seven, including BPC-157, KPV and TB-500. FDA's meeting page lists no minutes or vote record. The panel's advice is not binding. FDA said it would not make a final call until it had weighed that advice.

A lab report confirming 99% purity is about purity. It says nothing about whether a 503A pharmacy may use that compound. Is it pure, and is it legal, are answered by different bodies. Our breakdown of the 2026 FDA peptide vote covers what changed and what did not. The wider FDA reclassification explainer walks through how the 503A process works.

Can Peptide Lab Testing Tell You About a Drug Test?

No, peptide lab testing for purity does not answer drug test questions. WADA's 2026 banned list names BPC-157 in class S0 (WADA). S0 holds drugs that no government health agency has approved for treating people. Class S2 covers peptide hormones and growth factors. It includes GHRPs, peptides that make the body release growth hormone. Both S0 and S2 are prohibited at all times, in and out of competition. A lab that confirms purity or identity has no effect on that status.

Detection science is different from consumer purity testing. In 2011, a doping lab in Cologne set out an LC-MS test for GHRPs in urine (Thomas 2011). Ipamorelin was one of them. It could find as little as 0.2 to 1 ng/mL. A nanogram is a billionth of a gram.

A certificate of analysis speaks to what is in a vial, not to drug test status. Those are two different systems. Under WADA's code, using or trying to use a banned drug is itself a breach (WADA). So a ban does not need a positive test. See the BPC-157 WADA status guide for which compounds are covered.

What Does Peptide Testing Mean for Sourcing?

Peptide testing is one of three separate checks: purity, legal status and competition status. The 503A list changes only through FDA rules. WADA puts out its own list each year. Our sources page lists sellers that meet seven tests. One is an outside lab report for each batch.

Related reading: the peptide purity crisis. The case for formal peptide regulation. Peptide stacks that work. And where peptide legality stands in 2026.

References

1. Multifactor quality and safety analysis of semaglutide products sold online, 2024. PMC11582493
2. Regulatory guidelines for the analysis of therapeutic peptides. PMC11806371
3. Quality control of therapeutic peptides by NMR. PMC6452441
4. Determination of growth hormone releasing peptides in human urine for doping controls. PubMed 21298258
5. NIST, About NVLAP. NIST
6. FDA, Briefing Document introduction, PCAC, July 23-24, 2026. FDA
7. FDA, Briefing Document, BPC-157, July 2026. FDA
8. FDA, Briefing Document, TB-500, July 2026. FDA
9. FDA, Certain bulk drug substances for use in compounding that may present significant safety risks. FDA
10. FDA, July 23-24, 2026 PCAC meeting page. FDA
11. NCPA, 31 July 2026, FDA advisory committee nominates six peptides for pharmacies to compound. NCPA
12. WADA, 2026 Prohibited List. WADA
13. WADA, World Anti-Doping Code 2021. WADA